🇺🇸 PHTHALYLSULFATHIAZOLE in United States

69,632 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Systemic Lupus Erythematosus — 7,536 reports (10.82%)
  2. Pemphigus — 7,517 reports (10.8%)
  3. Pain — 7,469 reports (10.73%)
  4. Alopecia — 7,342 reports (10.54%)
  5. Abdominal Discomfort — 7,301 reports (10.49%)
  6. Rheumatoid Arthritis — 7,050 reports (10.12%)
  7. Glossodynia — 6,730 reports (9.67%)
  8. Fatigue — 6,356 reports (9.13%)
  9. Drug Ineffective — 6,233 reports (8.95%)
  10. Swelling — 6,098 reports (8.76%)

Source database →

PHTHALYLSULFATHIAZOLE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is PHTHALYLSULFATHIAZOLE approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for PHTHALYLSULFATHIAZOLE in United States?

Marketing authorisation holder not available in our data.